• Immunoprecise Antibodies Ltd IPA.OQ IPA.O is expected to show a rise in quarterly revenue when it reports results on December 10 for the period ending October 31 2024

• The Victoria British Columbia-based company is expected to report a 4.7% increase in revenue to C$6.439 million from C$6.15 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.

• ​LSEG's mean analyst estimate for Immunoprecise Antibodies Ltd is for a loss of 9 cents per share.

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for Immunoprecise Antibodies Ltd is $6.00​, above​ its last closing price of $0.37. ​​​

This summary was machine generated December 6 at 13:34 GMT. All figures in Canadian dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)